{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:51:02Z","timestamp":1792727462235,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41417-025-00976-8","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:19:38Z","timestamp":1760415578000},"page":"1439-1452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SMAD4-armed oncolytic adenovirus therapy potentiates the chemotherapy effects in NSCLC through suppression of the Wnt\/\u03b2-catenin pathway"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0760-1418","authenticated-orcid":false,"given":"Chuanjing","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3380-6945","authenticated-orcid":false,"given":"Sultan Muhammad","family":"Haris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1883-0670","authenticated-orcid":false,"given":"Biao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4836-8616","authenticated-orcid":false,"given":"Huaguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3115-8703","authenticated-orcid":false,"given":"Fang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4546-8179","authenticated-orcid":false,"given":"Yigang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"976_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2024","unstructured":"Filho AM, Laversanne M, Ferlay J, Colombet M, Pi\u00f1eros M, Znaor A, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2024;156:1336\u201346.","journal-title":"Int J Cancer"},{"key":"976_CR2","doi-asserted-by":"crossref","unstructured":"Zhu C, Zhuang W, Chen L, Yang W, Ou WB. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Transl Lung Cancer Res. 2020;9:111\u201338.","DOI":"10.21037\/tlcr.2020.01.09"},{"key":"976_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2020","unstructured":"Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol\/Hematol. 2020;157:103194.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"976_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345\u201356.","journal-title":"Nat Med"},{"key":"976_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2022","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J:. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2022;9:122\u201339.","journal-title":"Trends Cancer"},{"key":"976_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15229-5","volume":"11","author":"G Wang","year":"2020","unstructured":"Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun. 2020;11:1395.","journal-title":"Nat Commun"},{"key":"976_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.889403","volume":"9","author":"F Huang","year":"2022","unstructured":"Huang F, Dai C, Zhang Y, Zhao Y, Wang Y, Ru G. Development of molecular mechanisms and their application on oncolytic Newcastle disease virus in cancer therapy. Front Mol Biosci. 2022;9:889403.","journal-title":"Front Mol Biosci"},{"key":"976_CR8","doi-asserted-by":"crossref","unstructured":"Sultan MH, Zhan Q, Jin H, Jia X, Wang Y. Epigenetic modulation by oncolytic viruses: Implications for cancer therapeutic efficacy. Biochim Biophys Acta Rev Cancer. 2025;1880:189270.","DOI":"10.1016\/j.bbcan.2025.189270"},{"key":"976_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1272351","volume":"15","author":"SN Mirbahari","year":"2024","unstructured":"Mirbahari SN, Da Silva M, Z\u00fa\u00f1iga AIM, Kooshki Zamani N, St-Laurent G, Totonchi M, et al. Recent progress in combination therapy of oncolytic vaccinia virus. Front Immunol. 2024;15:1272351.","journal-title":"Front Immunol"},{"key":"976_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-023-02309-4","volume":"29","author":"H Soliman","year":"2023","unstructured":"Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023;29:450\u20137.","journal-title":"Nat Med"},{"key":"976_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/aps.2012.196","volume":"34","author":"W Lei","year":"2013","unstructured":"Lei W, Liu H-B, Wang S-B, Zhou X-M, Zheng S-D, Guo K-N, et al. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model. Acta Pharmacol Sin. 2013;34:531\u201340.","journal-title":"Acta Pharmacol Sin"},{"key":"976_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/aps.2017.91","volume":"39","author":"C Ying","year":"2017","unstructured":"Ying C, Xiao B-D, Qin Y, Wang B-R, Liu X-Y, Wang R-W, et al. GOLPH2-regulated oncolytic adenovirus, GD55, exerts strong killing effect on human prostate cancer stem-like cells in vitro and in vivo. Acta Pharmacol Sin. 2017;39:405\u201314.","journal-title":"Acta Pharmacol Sin"},{"key":"976_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/hum.2020.024","volume":"31","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Ye M, Huang F, Wang S, Wang H, Mou X, et al. Oncolytic adenovirus expressing ST13 increases antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic ductal adenocarcinoma. Hum Gene Ther. 2020;31:891\u2013903.","journal-title":"Hum Gene Ther"},{"key":"976_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3892\/mmr.2015.3355","volume":"12","author":"X Han","year":"2015","unstructured":"Han X, Wang S, Zhou W, Li Y, Lei W, Lv W. Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer. Mol Med Rep. 2015;12:435\u201341.","journal-title":"Mol Med Rep"},{"key":"976_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41419-020-03223-0","volume":"11","author":"H-J Hu","year":"2020","unstructured":"Hu H-J, Liang X, Li H-L, Du C-M, Hao J-L, Wang H-Y, et al. The armed oncolytic adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor cells from the self-state into the nonself-state besides direct killing. Cell Death Dis. 2020;11:1022.","journal-title":"Cell Death Dis"},{"key":"976_CR16","doi-asserted-by":"crossref","unstructured":"Gao C, Ying Q, Qiu Y, Ren N, Chen K, Zhou Y, et al. Oncolytic vaccinia virus harboring CLEC2A gene enhances viral replication and antitumor efficacy. Mol Ther Oncol. 2024;32:200823.","DOI":"10.1016\/j.omton.2024.200823"},{"key":"976_CR17","doi-asserted-by":"crossref","unstructured":"Geng JX, Lu YF, Zhou JN, Huang B, Qin Y. Exosome technology: A novel and effective drug delivery system in the field of cancer therapy. World J Gastrointest Oncol. 2025;17:101857.","DOI":"10.4251\/wjgo.v17.i3.101857"},{"key":"976_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","volume":"25","author":"BL Musher","year":"2024","unstructured":"Musher BL, Rowinsky EK, Smaglo BG, Abidi W, Othman M, Patel K, et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study. Lancet Oncol. 2024;25:488\u2013500.","journal-title":"Lancet Oncol"},{"key":"976_CR19","doi-asserted-by":"crossref","unstructured":"Ge Y, Lei W, Ma Y, Wang Y, Wei B, Chen X, et al. Synergistic antitumor effects of CDK inhibitor SNS\u2011032 and an oncolytic adenovirus co\u2011expressing TRAIL and Smac in pancreatic cancer. Mol Med Rep. 2017;15:3521-3528.","DOI":"10.3892\/mmr.2017.6472"},{"key":"976_CR20","doi-asserted-by":"crossref","unstructured":"Carbonero G-R, Peregrino B-M, Mart\u00edn M-G, \u00c1lvarez R, Macarulla T, Martinez M-R, et al. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J Immunother Cancer. 2022;10:3255.","DOI":"10.1136\/jitc-2021-003255"},{"key":"976_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4252\/wjsc.v14.i1.41","volume":"14","author":"C-J Dai","year":"2022","unstructured":"Dai C-J, Cao Y-T, Huang F, Wang Y-G. Multiple roles of mothers against decapentaplegic homolog 4 in tumorigenesis, stem cells, drug resistance, and cancer therapy. World J Stem Cells. 2022;14:41\u201353.","journal-title":"World J Stem Cells"},{"key":"976_CR22","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.celrep.2015.02.014","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu J, Cho S-N, Akkanti B, Jin N, Mao J, Long W, et al. ErbB2 pathway activation upon smad4 loss promotes lung tumor growth and metastasis. Cell Rep. 2015;10:1599\u2013613.","journal-title":"Cell Rep"},{"key":"976_CR23","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1158\/0008-5472.CAN-22-1247","volume":"82","author":"LP Loevenich","year":"2022","unstructured":"Loevenich LP, Tschurtschenthaler M, Rokavec M, Silva MG, Jesinghaus M, Kirchner T, et al. SMAD4 loss induces c-myc-mediated NLE1 upregulation to support protein biosynthesis, colorectal cancer growth, and metastasis. Cancer Res. 2022;82:4604\u201323.","journal-title":"Cancer Res"},{"key":"976_CR24","doi-asserted-by":"publisher","first-page":"117899","DOI":"10.1016\/j.biopha.2025.117899","volume":"184","author":"X Xue","year":"2025","unstructured":"Xue X, Zhou Y, Liu H, Gao Y, Ma X, Xiao Z, et al. A novel missense mutation Smad4 V354L enhances the efficacy of docetaxel in non-small cell lung cancer. Biomed Pharmacother Biomed Pharmacother. 2025;184:117899.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"key":"976_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41374-020-00517-x","volume":"101","author":"Y Wang","year":"2020","unstructured":"Wang Y, Xue Q, Zheng Q, Jin Y, Shen X, Yang M, et al. SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer. Lab Investig J Tech Methods Pathol. 2020;101:463\u201376.","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"976_CR26","doi-asserted-by":"crossref","unstructured":"Zhao Y, Liu H, Zhan Q, Jin H, Wang Y, Wang H, et al. Oncolytic adenovirus encoding LHPP exerts potent antitumor effect in lung cancer. Sci Rep. 2024;14:13108.","DOI":"10.1038\/s41598-024-63325-z"},{"key":"976_CR27","doi-asserted-by":"crossref","unstructured":"Xiao B, Zhang L, Liu H, Fang H, Wang C, Huang B, et al. Oncolytic adenovirus CD55-Smad4 suppresses cell proliferation, metastasis, and tumor stemness in colorectal cancer by regulating Wnt\/\u03b2-catenin signaling pathway. Biomedicines. 2020;8:593.","DOI":"10.3390\/biomedicines8120593"},{"key":"976_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12510-4","volume":"24","author":"J Hu","year":"2024","unstructured":"Hu J, Dai C, Ding Z, Pan Y, Lu L, Bao J, et al. IKBIP promotes tumor development via the Akt signaling pathway in esophageal squamous cell carcinoma. BMC Cancer. 2024;24:759.","journal-title":"BMC Cancer"},{"key":"976_CR29","doi-asserted-by":"publisher","first-page":"18201","DOI":"10.1007\/s00432-023-05501-8","volume":"149","author":"L Qiang","year":"2023","unstructured":"Qiang L, Huili Z, Leilei Z, Xiaoyan W, Hui W, Biao H, et al. Intratumoral delivery of a Tim-3 antibody-encoding oncolytic adenovirus engages an effective antitumor immune response in liver cancer. J Cancer Res Clin Oncol. 2023;149:18201\u201313.","journal-title":"J Cancer Res Clin Oncol"},{"key":"976_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.967708","volume":"10","author":"Y Sun","year":"2022","unstructured":"Sun Y, Wu W, Zhao Q, Jiang R, Li J, Wang L, et al. CircGSAP regulates the cell cycle of pulmonary microvascular endothelial cells via the miR-942-5p sponge in pulmonary hypertension. Front Cell Dev Biol. 2022;10:967708.","journal-title":"Front Cell Dev Biol"},{"key":"976_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.canlet.2018.01.031","volume":"418","author":"X Li","year":"2018","unstructured":"Li X, Li J, Cai Y, Peng S, Wang J, Xiao Z, et al. Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. Cancer Lett. 2018;418:211\u201320.","journal-title":"Cancer Lett"},{"key":"976_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","volume":"81","author":"W Xue","year":"2024","unstructured":"Xue W, Yang L, Chen C, Ashrafizadeh M, Tian Y, Sun R. Wnt\/\u03b2-catenin-driven EMT regulation in human cancers. Cell Mol Life Sci. 2024;81:79.","journal-title":"Cell Mol Life Sci"},{"key":"976_CR33","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94:1623\u201340.","journal-title":"Mayo Clin Proc"},{"key":"976_CR34","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DAE Cross","year":"2014","unstructured":"Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046\u201361.","journal-title":"Cancer Discov"},{"key":"976_CR35","doi-asserted-by":"crossref","unstructured":"Ye W, Lu X, Qiao Y, Ou WB. Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer. Biochim Biophys Acta Rev Cancer. 2024;1879:189108.","DOI":"10.1016\/j.bbcan.2024.189108"},{"key":"976_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","volume":"534","author":"Y Jia","year":"2016","unstructured":"Jia Y, Yun C-H, Park E, Ercan D, Manuia M, Juarez J, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534:129\u201332.","journal-title":"Nature"},{"key":"976_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663986","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Tang L, Zhou Y, He W, Li W. Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management. Front Immunol. 2021;12:663986.","journal-title":"Front Immunol"},{"key":"976_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28729","volume":"95","author":"Z Huang","year":"2023","unstructured":"Huang Z, Guo H, Lin L, Li S, Yang Y, Han Y, et al. Application of oncolytic virus in tumor therapy. J Med Virol. 2023;95:e28729.","journal-title":"J Med Virol"},{"key":"976_CR39","doi-asserted-by":"crossref","unstructured":"He Y, Huang X, Li X, Liu H, Liu M, Tao J, et al. Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial. J Immunother Cancer. 2024;12:8999.","DOI":"10.1136\/jitc-2024-008999"},{"key":"976_CR40","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-23-3874","volume":"30","author":"SA Pakola","year":"2024","unstructured":"Pakola SA, Peltola KJ, Clubb JHA, Jirovec E, Haybout L, Kudling TV, et al. Safety, efficacy, and biological data of t-cell-enabling oncolytic adenovirus tilt-123 in advanced solid cancers from the tunimo monotherapy phase I trial. Clin Cancer Res J Am Assoc Cancer Res. 2024;30:3715\u201325.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"976_CR41","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1002\/cncr.27535","volume":"118","author":"B Xu","year":"2012","unstructured":"Xu B, Zheng W-Y, Jin D-Y, Wang D-S, Liu X-Y, Qin X-Y. Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene. Cancer. 2012;118:5217\u201326.","journal-title":"Cancer"},{"key":"976_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/gt.2017.86","volume":"25","author":"A Galal El-Shemi","year":"2017","unstructured":"Galal El-Shemi A, Mohammed Ashshi A, Oh E, Jung BK, Basalamah M, Alsaegh A, et al. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma. Gene Ther. 2017;25:54\u201365.","journal-title":"Gene Ther"},{"key":"976_CR43","doi-asserted-by":"publisher","first-page":"e989133","DOI":"10.4161\/23723556.2014.989133","volume":"3","author":"H Demagny","year":"2015","unstructured":"Demagny H, De Robertis EM:. Smad4\/DPC4: a barrier against tumor progression driven by RTK\/Ras\/Erk and Wnt\/GSK3 signaling. Mol Cell Oncol. 2015;3:e989133.","journal-title":"Mol Cell Oncol"},{"key":"976_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.7150\/ijbs.23230","volume":"14","author":"M Zhao","year":"2018","unstructured":"Zhao M, Mishra L, Deng C-X. The role of TGF-\u03b2\/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14:111\u201323.","journal-title":"Int J Biol Sci"},{"key":"976_CR45","doi-asserted-by":"crossref","unstructured":"Yan Z, Shi Y, Yang R, Xue J, Fu C. ELABELA-derived peptide ELA13 attenuates kidney fibrosis by inhibiting the Smad and ERK signaling pathways. J Zhejiang Univ Sci B. 2024;25:341\u201353.","DOI":"10.1631\/jzus.B2300033"},{"key":"976_CR46","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/his.14880","volume":"82","author":"AH Bauer","year":"2023","unstructured":"Bauer AH, Basta DW, Hornick JL, Dong F. Loss of function SMAD4 nonstop mutations in human cancer. Histopathology. 2023;82:1098\u2013104.","journal-title":"Histopathology"},{"key":"976_CR47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/jclinpath-2018-205095","volume":"71","author":"AJ McCarthy","year":"2018","unstructured":"McCarthy AJ, Chetty R. Smad4\/DPC4. J Clin Pathol. 2018;71:661\u20134.","journal-title":"J Clin Pathol"},{"key":"976_CR48","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41401-023-01199-z","volume":"45","author":"H-D Chen","year":"2023","unstructured":"Chen H-D, Ye Z, Hu H-F, Fan G-X, Hu Y-H, Li Z, et al. SMAD4 endows TGF-\u03b21-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. Acta Pharmacol Sin. 2023;45:844\u201356.","journal-title":"Acta Pharmacol Sin"},{"key":"976_CR49","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41419-024-06838-9","volume":"15","author":"K Li","year":"2024","unstructured":"Li K, Shu D, Li H, Lan A, Zhang W, Tan Z, et al. SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR\u2009+\u2009HER2- breast cancer. Cell Death Dis. 2024;15:444.","journal-title":"Cell Death Dis"},{"key":"976_CR50","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","volume":"13","author":"Y Qian","year":"2020","unstructured":"Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13:130.","journal-title":"J Hematol Oncol"},{"key":"976_CR51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10555-017-9726-5","volume":"37","author":"D Huang","year":"2018","unstructured":"Huang D, Sun W, Zhou Y, Li P, Chen F, Chen H, et al. Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 2018;37:173\u201387.","journal-title":"Cancer Metastasis Rev"},{"key":"976_CR52","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt\/\u03b2-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6:307.","journal-title":"Signal Transduct Target Ther"},{"key":"976_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N Krishnamurthy","year":"2017","unstructured":"Krishnamurthy N, Kurzrock R. Targeting the Wnt\/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2017;62:50\u201360.","journal-title":"Cancer Treat Rev"},{"key":"976_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101838","volume":"5","author":"M Shi","year":"2024","unstructured":"Shi M, Yang Y, Huang N, Zeng D, Mo Z, Wang J, et al. Genetic and microenvironmental evolution of colorectal liver metastases under chemotherapy. Cell Rep Med. 2024;5:101838.","journal-title":"Cell Rep Med"},{"key":"976_CR55","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/1541-7786.MCR-20-0721","volume":"19","author":"CB Lanauze","year":"2021","unstructured":"Lanauze CB, Sehgal P, Hayer K, Torres-Diz M, Pippin JA, Grant SFA, et al. Colorectal cancer-associated Smad4 R361 hotspot mutations boost wnt\/\u03b2-catenin signaling through enhanced Smad4-LEF1 binding. Mol Cancer Res. 2021;19:823\u201333.","journal-title":"Mol Cancer Res"},{"key":"976_CR56","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/bjc.2013.125","volume":"108","author":"K Ueno","year":"2013","unstructured":"Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, et al. microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 2013;108:1659\u201367.","journal-title":"Br J Cancer"},{"key":"976_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216634","volume":"585","author":"A Bahreyni","year":"2024","unstructured":"Bahreyni A, Mohamud Y, Luo H. Oncolytic virus-based combination therapy in breast cancer. Cancer Lett. 2024;585:216634.","journal-title":"Cancer Lett"},{"key":"976_CR58","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373\u20139.","journal-title":"Cancer Sci"},{"key":"976_CR59","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-022-03334-x","volume":"72","author":"Y Kajiwara","year":"2022","unstructured":"Kajiwara Y, Tazawa H, Yamada M, Kanaya N, Fushimi T, Kikuchi S, et al. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunol, Immunother. 2022;72:1285\u20131300.","journal-title":"Cancer Immunol, Immunother"},{"key":"976_CR60","doi-asserted-by":"crossref","unstructured":"Khuri FR, Jain SR. Novel agents and incremental advances in the treatment of head and neck cancer. Semin Oncol. 2004;31:3\u201310.","DOI":"10.1053\/j.seminoncol.2004.02.011"},{"key":"976_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100639","volume":"45","author":"NH Goradel","year":"2020","unstructured":"Goradel NH, Baker AT, Arashkia A, Ebrahimi N, Ghorghanlu S, Negahdari B. Oncolytic virotherapy: challenges and solutions. Curr Probl Cancer. 2020;45:100639.","journal-title":"Curr Probl Cancer"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00976-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00976-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00976-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T23:02:22Z","timestamp":1765753342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00976-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00976-8","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The animal experiment was approved by the Ethics Committee of the College of Life Sciences and Medicine, Zhejiang Sci-Tech University (No. 20230111-01). This study meets the standards of animal ethics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}